Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Desiree Headley"'
Autor:
Miguel Martin, Roberto Hegg, Sung-Bae Kim, Michael Schenker, Daniela Grecea, Jose Angel Garcia-Saenz, Konstantinos Papazisis, QuChang Ouyang, Aleksandra Lacko, Berna Oksuzoglu, James Reeves, Meena Okera, Laura Testa, Chikako Shimizu, Neelima Denduluri, Hryhoriy Adamchuk, Shaker Dakhil, Ran Wei, Tammy Forrester, Maria Munoz Fernandez, Annamaria Zimmermann, Desiree Headley, Stephen R. D. Johnston
Publikováno v:
JAMA oncology. 8(8)
Patients selected to receive neoadjuvant chemotherapy (NAC) are usually those at higher risk of relapse, and there is a need to find better therapeutic options for these patients.To determine the efficacy and safety outcomes for patients with hormone
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1321a8c661a96b8eb37c44748231ef39
https://pubmed.ncbi.nlm.nih.gov/35653145
https://pubmed.ncbi.nlm.nih.gov/35653145
Autor:
Masakazu Toi, Joyce O'Shaughnessy, Investigators, Valentina Guarneri, Ran Wei, Maarten Hulstijn, Irfan Cicin, Mario Campone, Frances M. Boyle, Jens Huober, Patrick Neven, Erika Hamilton, Belen San Antonio, Morihito Okada, Sara M. Tolaney, Andrew M Wardley, Roberto Hegg, Desiree Headley, Stephen R. D. Johnston, Martin Frenzel, Q. Zhang, Priya Rastogi, Zhi Min Shao, Jorge Luis Martinez Rodriguez, Miguel Martín, Javier Cortes, Ian C. Smith, Nadia Harbeck, Joohyuk Sohn, Joanne Cox
Publikováno v:
Scientia
Journal of Clinical Oncology
Journal of Clinical Oncology
Càncer de mama precoç; Teràpia endocrina; Abemaciclib Cáncer de mama precoz; Terapia endocrina; Abemaciclib Early Breast Cancer; Endocrine Therapy; Abemaciclib PURPOSE Many patients with HR+, HER2− early breast cancer (EBC) will not experience
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c61493b64a595a77134a06669bf6fbf
https://pubmed.ncbi.nlm.nih.gov/35377771
https://pubmed.ncbi.nlm.nih.gov/35377771
Autor:
Z-M Shao, M. Martin, M. Campone, Ian C. Smith, Martin Frenzel, Joyce O'Shaughnessy, Frances M. Boyle, M. Toi, Valentina Guarneri, S.R.D. Johnston, R. Wei, Erika Hamilton, Roberto Hegg, Patrick Neven, Jung Ho Sohn, Joanne Cox, J. Cortés, Nadia Harbeck, Desiree Headley, Priya Rastogi
Publikováno v:
Annals of Oncology. 31:S1242-S1243
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::08fa725ee9201efd0c8f9b4dda70f860
https://doi.org/10.1016/j.annonc.2020.10.023
https://doi.org/10.1016/j.annonc.2020.10.023
Autor:
Nadia Harbeck, Joyce O'Shaughnessy, J. Cortés, M. Campone, Frances M. Boyle, Erika Hamilton, Joanne Cox, M. Martin, M. Toi, Z-M Shao, Patrick Neven, I. E. Smith, R. Wei, Roberto Hegg, Jung Ho Sohn, Valentina Guarneri, Martin Frenzel, Desiree Headley, Priya Rastogi, S.R.D. Johnston
Publikováno v:
Annals of Oncology. 31:S1143-S1144
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8e7beef7f93bce85a98e61969c61c7b8
https://doi.org/10.1016/j.annonc.2020.08.2238
https://doi.org/10.1016/j.annonc.2020.08.2238
Autor:
Chuan-gui Song, David Molthrop, Georgina Garnica Jaliffe, Joyce O'Shaughnessy, Maria Jose Muñoz, Masakazu Toi, Susana Barriga, Peter A. Fasching, Nadia Harbeck, Stephen Albert Johnston, Mahmut Gumus, Toshinari Yamashita, Valerie Andre, Michael Method, Desiree Headley, Priya Rastogi, Hans Kreipe, Ran Wei, Jacqueline Vuky, Miguel Martín
Publikováno v:
Cancer Research. 81:PD2-01
Background monarchE, a phase 3, open-label, randomized study evaluating endocrine therapy with or without abemaciclib in patients with node positive, HR+, HER2-, high risk early breast cancer, resulted in a statistically significant improvement in in
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::31e11f9e5be5dabc33ebf9b5bcdb2056
https://doi.org/10.1158/1538-7445.sabcs20-pd2-01
https://doi.org/10.1158/1538-7445.sabcs20-pd2-01
Autor:
Joyce O'Shaughnessy, Miguel Martin, Stephen R. D. Johnston, Masakazu Toi, Nadia Harbeck, Joanne Cox, Jennifer Wei, Desiree Headley, Priya Rastogi
Publikováno v:
Cancer Research. 80:OT2-02
Background: Abemaciclib is an oral selective inhibitor of CDK 4 & 6 administered on a continuous schedule and demonstrated clinically meaningful efficacy in patients with hormone-receptor-positive (HR+), human epidermal growth factor receptor 2-negat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::82d205eb261d02467bc630da3924c6e0
https://doi.org/10.1158/1538-7445.sabcs19-ot2-02-02
https://doi.org/10.1158/1538-7445.sabcs19-ot2-02-02
Autor:
T. Forrester, Quchang Ouyang, Daniela Grecea, María García Muñoz, Desiree Headley, James A. Reeves, Roberto Hegg, Annamaria Zimmermann, Meena Okera, Laura Testa, José A. García-Sáenz, Michael Schenker, Stephen R. D. Johnston, Sung Bae Kim, Chikako Shimizu, Ran Wei, Berna Oksuzoglu, Aleksandra Lacko, Miguel Martín, Konstantinos Papazisis
Publikováno v:
Web of Science
517 Background: monarchE, a phase 3, open-label, randomized study evaluating abemaciclib combined with adjuvant endocrine therapy (ET) compared to ET alone in patients with HR+, HER2-, high risk early breast cancer (EBC), resulted in a statistically
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bb43833ff0f59ba33cab15eef8e71a4
https://publons.com/wos-op/publon/51258469/
https://publons.com/wos-op/publon/51258469/
